Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer

Prior treatment

• Poor medication compliance.

Other illness

• Tumor-related emergencies requiring urgent treatment, such as malignant pericardial effusion or cardiac tamponade, superior vena cava syndrome, or spinal cord compression.
• Clinically significant bleeding tendency or coagulation disorders, such as hemophilia.
• HIV or syphilis infection; active hepatitis B or C:
  • Hepatitis B: HBV-DNA ≥ 1000 IU/mL.
  • Hepatitis C: Positive HCV RNA with abnormal liver function.
• History of involuntary commitment due to psychiatric disorders or other psychological conditions deemed unsuitable for treatment by the investigator.
• Presence of other autoimmune diseases, or long-term use of immunosuppressive agents or corticosteroids.
• Any other condition that the investigator considers grounds for exclusion.

Lab values

• Significant cardiovascular diseases, including:
  • Documented cardiovascular events within the past 6 months, such as myocardial infarction, angina, heart failure, severe arrhythmia, or having undergone angioplasty, stent implantation, or coronary artery bypass surgery.
  • Clinically significant QT/QTcF prolongation (QT/QTcF \> 470 ms in females or \> 450 ms in males).

Other

• Pathologically confirmed mixed histology, such as adenosquamous carcinoma of the lung.

• Pathologically confirmed stage IV non-small cell lung cancer (NSCLC) with at least one measurable lesion according to RECIST 1.1 criteria (i.e., a lesion with the longest diameter ≥10 mm on spiral CT scan or a lymph node with a short axis ≥15 mm).
• Tumor tissue tested positive for EphA2 expression by immunohistochemistry (≥20%).
• Disease progression after standard treatment or no available standard treatment (patients must have received at least two prior systemic therapies, including but not limited to chemotherapy and immune checkpoint inhibitors; patients with actionable driver mutations must have failed targeted therapy).
• ECOG performance status: 0-1.
• Expected survival ≥6 months.
• Toxicities related to prior anti-tumor treatments must have resolved to baseline levels or ≤ Grade 1 (excluding residual alopecia); Grade ≤2 neurotoxicity is acceptable. Washout periods: 4 weeks for chemotherapy and immunotherapy, 2 weeks for targeted therapy.
• Adequate organ function, including:
  • Adequate hematologic function: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelet count ≥75×10\^9/L, hemoglobin ≥9 g/dL. No transfusions, granulocyte colony-stimulating factor (G-CSF), thrombopoietin, or erythropoietin allowed within 14 days before blood tests.
  • Adequate hepatic function: Total bilirubin (TBIL) \<1.5× upper limit of normal (ULN); AST and ALT \<2.5×ULN. For patients with Gilbert's syndrome, TBIL \<2×ULN; if liver metastases are present, AST and ALT \<5×ULN.
  • Adequate renal function: Serum creatinine (Cr) ≤1.5×ULN, or if Cr \>1.5×ULN, creatinine clearance (CrCl) ≥60 mL/min calculated using the Cockcroft-Gault formula.
  • Adequate coagulation function: Prothrombin time (PT) and activated partial thromboplastin time (APTT) \<1.5×ULN; international normalized ratio (INR) \<1.5 or within the target range if on anticoagulant therapy.
• Subjects of reproductive potential must be willing to use effective contraception.
• Ability to understand and voluntarily sign the informed consent form.
• Willingness to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.